These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 18536520

  • 1. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.
    Skogseth R, Mulugeta E, Jones E, Ballard C, Rongve A, Nore S, Alves G, Aarsland D.
    Dement Geriatr Cogn Disord; 2008; 25(6):559-63. PubMed ID: 18536520
    [Abstract] [Full Text] [Related]

  • 2. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeckhoven C, De Deyn PP.
    Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
    [Abstract] [Full Text] [Related]

  • 3. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [Abstract] [Full Text] [Related]

  • 4. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM.
    Neurology; 2009 Mar 24; 72(12):1056-61. PubMed ID: 19307538
    [Abstract] [Full Text] [Related]

  • 5. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
    Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, Matsui T, Higuchi S, Matsushita S, Yoshida H, Sasaki H.
    Exp Neurol; 2001 Dec 24; 172(2):433-6. PubMed ID: 11716567
    [Abstract] [Full Text] [Related]

  • 6. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
    Stuerenburg HJ, Ganzer S, Müller-Thomsen T.
    Neuro Endocrinol Lett; 2005 Dec 24; 26(6):696-8. PubMed ID: 16380679
    [Abstract] [Full Text] [Related]

  • 7. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
    Schoonenboom NS, van der Flier WM, Blankenstein MA, Bouwman FH, Van Kamp GJ, Barkhof F, Scheltens P.
    Neurobiol Aging; 2008 May 24; 29(5):669-75. PubMed ID: 17208336
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type.
    Fellgiebel A, Kojro E, Müller MJ, Scheurich A, Schmidt LG, Fahrenholz F.
    J Geriatr Psychiatry Neurol; 2009 Mar 24; 22(1):3-9. PubMed ID: 19073834
    [Abstract] [Full Text] [Related]

  • 10. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L, Blennow K, Lundh T, Londos E, Minthon L.
    Dement Geriatr Cogn Disord; 2009 Mar 24; 28(1):88-94. PubMed ID: 19672066
    [Abstract] [Full Text] [Related]

  • 11. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P.
    Biol Psychiatry; 2008 Nov 15; 64(10):850-5. PubMed ID: 18395699
    [Abstract] [Full Text] [Related]

  • 12. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
    Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R.
    Ann Neurol; 1995 Oct 15; 38(4):643-8. PubMed ID: 7574461
    [Abstract] [Full Text] [Related]

  • 13. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.
    Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M, Alafuzoff I, Blennow K, Andreasen N, Vanmechelen E, Grundke-Iqbal I.
    Ann Neurol; 2005 Nov 15; 58(5):748-57. PubMed ID: 16247771
    [Abstract] [Full Text] [Related]

  • 14. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM.
    Neurology; 2009 Oct 27; 73(17):1353-8. PubMed ID: 19858456
    [Abstract] [Full Text] [Related]

  • 15. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M.
    J Neurol Sci; 2006 Dec 21; 251(1-2):124-8. PubMed ID: 17097109
    [Abstract] [Full Text] [Related]

  • 16. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K.
    Neurosci Lett; 2008 Aug 01; 440(2):145-9. PubMed ID: 18555606
    [Abstract] [Full Text] [Related]

  • 17. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, Frölich L, Schröder J, Schönknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Möller HJ, Kurz A, Basun H.
    J Clin Psychiatry; 2009 Jun 01; 70(6):922-31. PubMed ID: 19573486
    [Abstract] [Full Text] [Related]

  • 18. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E, Blennow K, Minthon L, Wiltfang J.
    Neurodegener Dis; 2008 Jun 01; 5(5):268-76. PubMed ID: 18309230
    [Abstract] [Full Text] [Related]

  • 19. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease.
    Yaka E, Egrilmez MY, Keskinoglu P, Cavdar Z, Genc S, Genc K, Iyilikci L, Yener GG.
    Cell Biochem Funct; 2009 Aug 01; 27(6):395-401. PubMed ID: 19639578
    [Abstract] [Full Text] [Related]

  • 20. [Neurochemical early and differential diagnostics for Alzheimer's disease].
    Wiltfang J, Lewczuk P, Maler M, Bleich S, Smirnov A, Kornhuber J.
    MMW Fortschr Med; 2004 Sep 16; 146(38):38-40. PubMed ID: 15532429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.